Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT ‐3 Versus ONWARDS 2, and QWINT ‐4 Versus ONWARDS 4
Primary result · Change from baseline in HbA1c (%), basal insulin-experiencedResult — go to the resultMD 0.137 % 95% CI −0.058 to 0.333Authors' conclusion
These indirect comparisons suggest that efsitora had lower event rates of hypoglycaemia and less weight gain compared to icodec in basal insulin-experienced participants. Efsitora was comparable to icodec for all other endpoints.
Study context
- Population
- Insulin-experienced individuals with T2D: basal insulin-experienced (QWINT-3 vs ONWARDS 2) and basal-bolus insulin-experienced (QWINT-4 vs ONWARDS 4)
- Comparison
- Insulin efsitora alfa vs insulin icodec
Methodological detailsmatching-adjusted indirect treatment comparisons, QWINT-3 vs ONWARDS 2, QWINT-4 vs ONWARDS 4
- Matching-adjusted indirect treatment comparisons
- QWINT-3 vs ONWARDS 2
- QWINT-4 vs ONWARDS 4
Primary result
As reported in the abstract
Change from baseline in HbA1c (%), basal insulin-experienced
MD
0.137 %
95% CI −0.058 to 0.333
Efsitoravs Icodec
MD 0.137 % (95% CI −0.058 to 0.333)
Further findings
| Outcome | MD (CI) | |
|---|---|---|
| Change from baseline in DTSQc, basal insulin-experienced | 1.01 (−0.243 to 2.27) | |
| −10123Difference (linear scale) |
| Outcome | MD (kg) (CI) | |
|---|---|---|
| Weight gain, basal insulin-experienced | −1.52 (−2.60 to −0.447) | |
| Change from baseline in body weight, basal-bolus insulin-experienced | −0.316 (−1.45 to 0.817) | |
| −4−202Difference, kg (linear scale) |
| Outcome | MD (%) (CI) | |
|---|---|---|
| Change from baseline in HbA1c (%), basal-bolus insulin-experienced | −0.0447 (−0.252 to 0.163) | |
| −0.4−0.200.2Difference, % (linear scale) |
Weight gain, basal insulin-experienced
- Efsitora exhibited significantly reduced weight gain vs icodec
Safety
| Outcome | Risk difference (95% CI) | |
|---|---|---|
| Discontinuation of treatment due to adverse event (basal insulin-experienced; QWINT-3 vs ONWARDS 2)Comparable · matching-adjusted indirect comparison | −0.0002 (−0.0223 to 0.0220) | |
| −0.03−0.02−0.0100.010.020.03Difference (linear scale) |
| Outcome | Estimate | |
|---|---|---|
| Level 2 or 3 hypoglycaemia (basal insulin-experienced; QWINT-3 vs ONWARDS 2)Efsitoravs IcodecLower event rates with efsitora · matching-adjusted indirect comparison | rate ratio (event rate) 0.436 (95% CI 0.241–0.786) | |
| Level 2 or 3 hypoglycaemia (basal insulin-experienced; QWINT-3 vs ONWARDS 2)Efsitoravs IcodecMatching-adjusted indirect comparison | OR (proportion of participants) 0.581 (95% CI 0.294–1.14) | |
| Level 2 or 3 hypoglycaemia (basal-bolus insulin-experienced; QWINT-4 vs ONWARDS 4)Efsitoravs IcodecComparable · matching-adjusted indirect comparison | OR (proportion of participants) 1.10 (95% CI 0.698–1.73) | |
| Level 2 or 3 hypoglycaemia (basal-bolus insulin-experienced; QWINT-4 vs ONWARDS 4)Efsitoravs IcodecComparable · matching-adjusted indirect comparison | rate ratio (event rate) 1.03 (95% CI 0.759–1.39) | |
| 0.20.5125Ratio (log scale) |
Original publication
Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT ‐3 Versus ONWARDS 2, and QWINT ‐4 Versus ONWARDS 4. Diabetes Obes Metab. Published 1 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →